Drug Profile
KBP 5695
Alternative Names: 5695; KBP-5695Latest Information Update: 28 Sep 2022
Price :
$50
*
At a glance
- Originator XuanZhu Pharma
- Class Antihyperglycaemics
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Diabetes mellitus
Most Recent Events
- 28 Sep 2022 No recent reports of development identified for preclinical development in Diabetes-mellitus in China
- 30 Aug 2018 KBP 5695 is still in preclinical development for Diabetes mellitus in China (XuanZhu Pharma pipeline, August 2018)
- 28 Jun 2018 No recent reports of development identified for preclinical development in Diabetes-mellitus in China